You are about to leave EKTERLYHCP.com
You will be redirected to a third-party website
not affiliated with KalVista Pharmaceuticals.
Attack and
Treatment Burden
A dual burden1-3
Despite prophylaxis, many patients with HAE continue to experience attacks1,3
In the previous 12 months,
90% of patients experienced attacks
despite prophylaxis3,*
Although guideline-recommended prophylaxis use reduces attack frequency, attacks may continue
in all anatomic locations, including life-threatening laryngeal attacks.1,5
When an attack occurs, the decision to treat is often delayed, or the attack is not treated with injectable on-demand treatment2
57% of patients
don’t treat
all of their attacks2,§
Burdens of current on-demand infusions or injections can cause significant treatment delays or nontreatment2,§
Up to
83 %
of patients taking HAE
treatment were anxious
when
anticipating use of on-demand
injections or infusions2,§
Reasons for delayed treatment or nontreatment with on-demand injections or infusions (responses from patients who delayed treatment)2,§
88%
Attack perceived not to be severe enough2
72%
Prefer to treat at home2
32%
On-demand treatment is bulky7
29%
Could trigger a security check7
28%
Treatment is “too painful”2
27%
Lack of privacy2
21%
Embarrassment8
HAE treatment guidelines
On-demand treatment is the essential component
of HAE management5
Keep on-demand treatment immediately available
Treat early to stop attacks from getting worse
All attacks are eligible for treatment regardless of location or severity
“AS PHYSICIANS, WE HAVE TO WALK A FEW STEPS IN PATIENTS’ SHOES…
WE CAN CLOSE THOSE GAPS BETWEEN WHERE WE ARE, WHERE THE GUIDELINES ARE, AND WHERE THE PATIENT IS.”
Allergy/Immunology Specialist
*Data were derived from a US-based retrospective, real-world survey using the Adelphi HAE Disease Specific Program database (July-November 2021).3
†Data were derived from a retrospective, real-world study of 334 patients taking long-term prophylaxis using the IQVIA PharMetrics© Plus database (January 1, 2016-September 30, 2023).4
‡According to a 2023 US HAE Association survey of 94 patients taking either on-demand treatment or prophylaxis + on-demand treatment.6
§According to a 2022 US HAE Association survey of 107 patients taking either on-demand or prophylaxis + on-demand treatment.2
HAE=hereditary angioedema; HAEA=US Hereditary Angioedema Association.
References:
1. Longhurst H. Optimum use of acute treatments for hereditary angioedema: evidence-based expert consensus. Front Med (Lausanne). 2018;4:245. doi:10.3389/fmed2017.00245
2. Betschel SD, Caballero T, Jones DH, et al. The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks. Allergy Asthma Clin Immunol. 2024;20(1):43. doi:10.1186/s13223-024-00903-w
3. Anderson J, Soteres D, Tachdjian R, et al. Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis. Allergy Asthma Proc. 2024;45(6):426-433. doi:10.2500/aap.2024.45.240046
4. Data on File. KalVista Pharmaceuticals, Inc. 2024.
5. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046
6. Christiansen S, O’Connor M, Craig T, et al. On-demand treatment of hereditary angioedema attacks: patient-reported utilization, barriers, and outcomes. Ann Allergy Asthma Immunol. 2025;134:570-579. doi:10.1016/j.anai.2024.12.012
7. Betschel S, van Kooten S, Heckmann M, Danese S, Goga L, Guilarte M. HAE patients decision to carry on-demand treatment when away from home. Abstract presented at: 13th C1-inhibitor Deficiency & Angioedema Workshop; May 4-7, 2023; Budapest, Hungary.
8. Busse P, Geng B, van Kooten S, et al. The impact of on-demand treatment on quality of life of people with HAE. J Allergy Clin Immunol. 2024;153(2)Supplement:AB88. doi:10.1016/j.jaci.2023.11.292